Vertex Pharmaceuticals (VRTX) Stock News

Vertex Pharmaceuticals (VRTX) presented positive Phase 1/2 data for zimislecel (VX-880), a stem cell-derived islet cell therapy for type 1 diabetes, at the American Diabetes Association conference. The study included 12 patients who received a full dose and were followed for at least one year. All patients achieved ADA-recommended targets of HbA1c 7% and 70% time-in-range, with 10 out of 12 becoming insulin-free. The therapy demonstrated consistent and durable benefits, with all patients showing glucose-responsive endogenous C-peptide production and freedom from severe hypoglycemic events after day 90. The treatment was generally well-tolerated, with most adverse events being mild or moderate. Two patient deaths occurred but were unrelated to zimislecel. The data was simultaneously published in the New England Journal of Medicine, and Vertex plans potential regulatory submissions next year.

Vertex Pharmaceuticals presented new data at the European Cystic Fibrosis Conference demonstrating the benefits of ALYFTREK and the importance of lower sweat chloride levels in cystic fibrosis treatment. The pooled analysis showed that reducing sweat chloride levels below 60 mmol/L led to improved outcomes, including better lung function, fewer pulmonary exacerbations, improved nutritional status, and enhanced quality of life. Notably, levels below 30 mmol/L showed even greater numerical benefits. Post hoc analysis from Phase 3 trials indicated that ALYFTREK treatment resulted in better health-related quality of life outcomes in adolescents and adults compared to TRIKAFTA, while also improving CF symptoms and general functioning in children aged 6-11 years.

Vertex Pharmaceuticals (NASDAQ: VRTX) has announced its management team's participation in three upcoming investor conferences in May and June 2025:

1. Evercore Biotechnology Summit (May 21) - Featuring Susie Lisa, SVP of Investor Relations, and Manisha Pai, Executive Director of IR

2. Bernstein 41st Annual Strategic Decisions Conference (May 30) - CEO Dr. Reshma Kewalramani will participate in a fireside chat at 8:00 a.m. ET

3. Goldman Sachs 46th Annual Global Healthcare Conference (June 10) - Dr. Kewalramani and Dr. David Altshuler, EVP of Global Research and CSO, will join a fireside chat at 2:40 p.m. ET

Live webcasts will be available on Vertex's website with replays archived in the Investors section.

Vertex Pharmaceuticals (VRTX) reported Q1 2025 financial results with total revenue of $2.77 billion, up 3% year-over-year. U.S. revenue increased 9% to $1.66 billion, while international revenue declined 5% to $1.11 billion due to IP violations in Russia. The company raised its 2025 revenue guidance to $11.85-$12 billion. GAAP net income was $646 million, down from $1.1 billion in Q1 2024, impacted by a $379 million impairment charge for VX-264. Key highlights include strong TRIKAFTA/KAFTRIO performance, successful launches of CASGEVY, ALYFTREK, and JOURNAVX, with over 20,000 JOURNAVX prescriptions filled since March. The company maintains robust cash position of $11.4 billion and continues advancing multiple clinical programs, including povetacicept and zimislecel Phase 3 trials.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced that Paul Negulescu, Ph.D., Senior Vice President, has been awarded the prestigious 2025 Canada Gairdner International Award for his groundbreaking research in cystic fibrosis (CF). The award recognizes his pioneering work in understanding CF's cellular and molecular mechanisms, leading to transformative drug therapies.

Under Negulescu's leadership, Vertex developed the first-ever protein folding corrector medicines that treat CF's underlying cause. The company's most recent achievement is a triple combination therapy that can treat over 90% of CF patients with more than 300 different mutations through once-daily dosing.

Vertex currently has five approved CF medicines that restore function of the defective CFTR protein. The research team continues to develop new therapies, including an mRNA approach in clinical development, targeting the remaining 10% of patients who don't respond to existing treatments.

Vertex Pharmaceuticals (Nasdaq: VRTX) has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results.

Investors can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and referencing the 'Vertex Pharmaceuticals First Quarter 2025 Earnings Call.' A live webcast will be available through the Investors section of Vertex's website at www.vrtx.com. Participants are advised to register 15 minutes before the scheduled webcast to ensure timely connection. An archived version of the webcast will be available on the company's website.

Vertex Pharmaceuticals (VRTX) has received European Commission approval for an expanded label of KAFTRIO® in combination with ivacaftor for treating cystic fibrosis (CF). The expansion covers patients aged 2 years and older with at least one non-class I mutation in the CFTR gene.

This regulatory approval makes approximately 4,000 additional people in the European Union eligible for this treatment that addresses the underlying cause of their disease. Several countries including Austria, Denmark, Ireland, Norway, Sweden, and Germany will provide immediate access to eligible patients through existing reimbursement agreements.

Vertex Pharmaceuticals (VRTX) has announced significant updates to its Type 1 diabetes (T1D) portfolio. The company reported that while VX-264, their encapsulated pancreatic islet cell therapy, was safe and well-tolerated, it failed to meet efficacy endpoints and will not advance further in clinical trials.

On a positive note, zimislecel (formerly VX-880), their fully differentiated islet cell therapy, is progressing well in Phase 3 trials. The pivotal trial is expected to complete enrollment and dosing in H1 2025, with global regulatory submissions planned for 2026. If approved, zimislecel could benefit approximately 60,000 people with severe T1D across the U.S. and Europe.

The company continues to pursue research-stage T1D programs, including alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel encapsulation devices.

Vertex Pharmaceuticals (VRTX) has received UK MHRA approval for ALYFTREK®, a once-daily triple combination CFTR modulator therapy for cystic fibrosis treatment. The medication is approved for patients 6 years and older with at least one F508del mutation or another responsive mutation in the CFTR gene.

In head-to-head clinical trials, ALYFTREK demonstrated non-inferior ppFEV1 results and improved sweat chloride levels compared to existing treatments. This marks Vertex's fifth CFTR modulator regimen, offering a more flexible and less burdensome treatment option.

The company is currently working with NICE and NHS to ensure patient access in the UK. ALYFTREK received FDA approval in December 2024, with additional regulatory applications pending in Europe, Canada, Switzerland, Australia, and New Zealand.